An international team of experts has published new guidelines for diagnosing and treating hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)…
Articles by Marisa Horak, MS
Oct. 26 is World Amyloidosis Day, and advocates around the world are joining together to shine a light on…
Attruby (acoramidis) was associated with better heart-related outcomes and a lower risk of hospitalization than Vyndamax (tafamidis) among…
Attruby (acoramidis) may be better than Vyndamax (tafamidis) at preserving heart health among people with transthyretin amyloid…
A newly developed questionnaire may help flag early signs of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) in people carrying mutations…
The approved therapy Attruby (acoramidis) may not only slow the progression of transthyretin amyloid cardiomyopathy (ATTR-CM), but it…
In people with transthyretin amyloid cardiomyopathy (ATTR-CM), treatment with the approved therapy Amvuttra (vutrisiran) may help reduce the risk…
Biopsies taken during surgery for carpal tunnel syndrome, a condition that affects a wrist nerve, may help with early…
Although mutations that cause hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) most frequently lead to nerve damage, they can also…
Regulatory authorities in the European Union (EU) have recommended approval of Tafamidis Accord, a generic version of Vyndaqel (tafamidis), an approved…